A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract

Annals of Oncology

Volumn 8, Issue 3, 1997, Pages 294-296

  Braybrooke, J P ^a   O'Byrne, K J ^a   Saunders, M P ^a   Propper, D J ^a   Salisbury, A J ^a   Boardman, P ^b   Taylor, M ^a   Ganesan, T S ^a   Talbot, D C ^a   Harris, A L ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

advanced gastric cancer; mitomycin C; oral etoposide

Indexed keywords

DEXAMETHASONE; ETOPOSIDE; METOCLOPRAMIDE; MITOMYCIN C;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; VOMITING;

EID: 8244228676     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008295926603     Document Type: Article

References (8)

1. Moertel C. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36: 675-82.
2. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996; 23: 397-406.
3. Kelsen DP, Magill GB, Cheng E et al. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 1983; 67: 509-10.
4. Taal BG, Teller FG, Ten-Bokkel-Huinink WW et al. Etoposide. leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: Experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994; 5: 90-2.
5. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993; 4: 533-43.
6. Slevin ML, Joel SP. Prolonged oral etoposide in small cell lung cancer. Ann Oncol 1993; 4: 529-32.
7. Jonkman-de Vries JD, Rosing H, Van Tellingen O et al. Pharmacokinetics of etoposide after oral and intravenous adminstration in patients with gastric carcinoma. Clin Drug Invest 1995; 10: 86-95.
8. Joel SP, Dolega-Ossowski E, Jones K et al. The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose (meeting abstract). Proc Am Assoc Cancer Res 1991; 32: 178 (Abstr 1061).